Climb Bio Total Long-Term Assets 2021-2024 | CLYM

Climb Bio total long-term assets from 2021 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current

Climb Bio Total Long-Term Assets 2021-2024 | CLYM

Climb Bio total long-term assets from 2021 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.4B
Vertex Pharmaceuticals (VRTX)$125.1B
Regeneron Pharmaceuticals (REGN)$111.8B
Bristol Myers Squibb (BMY)$106.8B
Gilead Sciences (GILD)$105.9B
CSL (CSLLY)$97.5B
GSK (GSK)$81.1B
Alnylam Pharmaceuticals (ALNY)$36.4B
Argenex SE (ARGX)$32.5B
BioNTech SE (BNTX)$28.6B
Biogen (BIIB)$27.9B
Illumina (ILMN)$23.7B
Moderna (MRNA)$22.2B
BeiGene (BGNE)$22.1B
Genmab (GMAB)$15.7B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$13.1B
Insmed (INSM)$12.9B
Vaxcyte (PCVX)$12.6B
Incyte (INCY)$12.6B
Sarepta Therapeutics (SRPT)$11.9B
Bio-Techne Corp (TECH)$11.7B
QIAGEN (QGEN)$10.1B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$9.1B
Roivant Sciences (ROIV)$8.8B
Revolution Medicines (RVMD)$8.2B
Repligen (RGEN)$8B
Intra-Cellular Therapies (ITCI)$7.8B
Ascendis Pharma (ASND)$7.8B